长效β2受体激动剂（LABA）用于慢性阻塞性肺疾病：疗效与安全性
Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety.
作者信息
Rossi Andrea, Khirani Sonia, Cazzola Mario
机构信息
Unit of Respiratory Diseases, Hospital of Bergamo, Bergamo, Italy.
出版信息
Int J Chron Obstruct Pulmon Dis. 2008;3(4):521-9. doi: 10.2147/copd.s1353.
Abstract
COPD is characterized by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy. The management of patients with COPD has taken a totally new direction over the past 20 years, thank to the use of novel therapies aimed to improve and modify the natural history of COPD. Long-acting bronchodilators, including long-acting beta2-agonists (LABAs), were introduced several years ago in order to enhance improvements in lung function, health status related quality of life, and reduce the rate of exacerbations. These effects can be boosted by the combination of LABAs with long-acting anticholinergic, and/or with inhaled corticosteroids. Inhaled LABAs are commonly well tolerated although adverse effects such as tremor and palpitations are occasionally troublesome.
摘要
慢性阻塞性肺疾病（COPD）的特征是气流进行性受阻，吸入或口服药物治疗无法使其完全逆转。在过去20年里，COPD患者的管理已朝着全新方向发展，这得益于使用旨在改善和改变COPD自然病程的新型疗法。长效支气管扩张剂，包括长效β2受体激动剂（LABAs），于数年前被引入，以增强肺功能改善、与健康状况相关的生活质量，并降低急性加重率。LABAs与长效抗胆碱能药物和/或吸入性糖皮质激素联合使用可增强这些效果。吸入性LABAs通常耐受性良好，尽管震颤和心悸等不良反应偶尔会造成困扰。
相似文献
1
Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety.长效β2受体激动剂（LABA）用于慢性阻塞性肺疾病：疗效与安全性
Int J Chron Obstruct Pulmon Dis. 2008;3(4):521-9. doi: 10.2147/copd.s1353.
2
Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?吸入性抗胆碱能药物与β2肾上腺素能受体激动剂联合治疗慢性阻塞性肺疾病是否合理？
Drugs Aging. 2007;24(8):615-28. doi: 10.2165/00002512-200724080-00001.
3
Inhaled therapy for stable chronic obstructive pulmonary disease.稳定期慢性阻塞性肺疾病的吸入治疗
Expert Opin Pharmacother. 2007 Apr;8(6):777-85. doi: 10.1517/14656566.8.6.777.
4
Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.长效支气管扩张剂和吸入性皮质类固醇单药及联合治疗晚期 COPD。
Semin Respir Crit Care Med. 2010 Jun;31(3):321-33. doi: 10.1055/s-0030-1254072. Epub 2010 May 21.
5
Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.长效β-激动剂及其在 COPD 中与吸入性皮质类固醇的关联。
Curr Med Chem. 2013;20(12):1477-95. doi: 10.2174/0929867311320120003.
6
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.长效β-激动剂在慢性阻塞性肺疾病管理中的应用：现有和未来的药物。
Respir Res. 2010 Oct 29;11(1):149. doi: 10.1186/1465-9921-11-149.
7
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.基于疾病表型，在日本慢性阻塞性肺疾病治疗中长效抗胆碱能药物/长效β2受体激动剂与吸入性糖皮质激素/长效β2受体激动剂的比较
Int J Chron Obstruct Pulmon Dis. 2015 Jun 10;10:1093-102. doi: 10.2147/COPD.S72858. eCollection 2015.
8
Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease.支气管扩张剂联合疗法治疗慢性阻塞性肺疾病
Curr Clin Pharmacol. 2011 Feb;6(1):48-61. doi: 10.2174/157488411794941331.
9
Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease.噻托溴铵及其他长效支气管扩张剂对慢性阻塞性肺疾病的影响。
Pulm Pharmacol Ther. 2006;19(2):112-9. doi: 10.1016/j.pupt.2005.04.003. Epub 2005 Jun 20.
10
Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β-agonist bronchodilators.目前有证据表明，使用长效抗胆碱能药物/长效β受体激动剂双支气管扩张剂治疗 COPD 有效。
Postgrad Med. 2020 Mar;132(2):198-205. doi: 10.1080/00325481.2019.1702834. Epub 2020 Jan 3.
引用本文的文献
1
The Effect of Inhaled Beta-2 Agonists on Heart Rate in Patients With Asthma: Sensor-Based Observational Study.吸入性β-2激动剂对哮喘患者心率的影响：基于传感器的观察性研究。
JMIR Cardio. 2024 Dec 11;8:e56848. doi: 10.2196/56848.
2
Challenges and Opportunities in COPD Management in Latin America: A Review of Inhalation Therapies and Advanced Drug Delivery Systems.拉丁美洲慢性阻塞性肺疾病管理中的挑战与机遇：吸入疗法和先进药物递送系统综述
Pharmaceutics. 2024 Oct 11;16(10):1318. doi: 10.3390/pharmaceutics16101318.
3
Lung Hyperinflation as Treatable Trait in Chronic Obstructive Pulmonary Disease: A Narrative Review.肺过度充气可作为慢性阻塞性肺疾病的一种可治疗的特征：一项叙述性综述。
Int J Chron Obstruct Pulmon Dis. 2024 Jul 2;19:1561-1578. doi: 10.2147/COPD.S458324. eCollection 2024.
4
Health-related quality of life and its associated factors in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者的健康相关生活质量及其相关因素。
PLoS One. 2023 Oct 26;18(10):e0293342. doi: 10.1371/journal.pone.0293342. eCollection 2023.
5
The Complex Association between COPD and COVID-19.慢性阻塞性肺疾病（COPD）与2019冠状病毒病（COVID-19）之间的复杂关联。
J Clin Med. 2023 May 31;12(11):3791. doi: 10.3390/jcm12113791.
6
Effects of LAMA/LABA Alone and in Combination on Cardiac Safety.长效抗胆碱能药物/长效β2受体激动剂单用及联用对心脏安全性的影响。
Int J Chron Obstruct Pulmon Dis. 2020 Aug 10;15:1931-1933. doi: 10.2147/COPD.S246356. eCollection 2020.
7
Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics.脂质纳米颗粒作为吸入疗法的给药载体
Biomedicines. 2022 Sep 2;10(9):2179. doi: 10.3390/biomedicines10092179.
8
Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease.靶向治疗慢性阻塞性肺疾病的衰老途径。
Int J Mol Sci. 2020 Sep 21;21(18):6924. doi: 10.3390/ijms21186924.
9
Inhaled corticosteroids, blood eosinophils, and FEV decline in patients with COPD in a large UK primary health care setting.在英国大型初级医疗保健环境中，吸入皮质类固醇、血嗜酸性粒细胞与 COPD 患者的 FEV 下降。
Int J Chron Obstruct Pulmon Dis. 2019 May 23;14:1063-1073. doi: 10.2147/COPD.S200919. eCollection 2019.
10
Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.长效支气管扩张剂固定剂量组合在 COPD 管理中的应用：全球和亚洲视角。
Adv Ther. 2019 Mar;36(3):495-519. doi: 10.1007/s12325-019-0893-3. Epub 2019 Feb 11.
本文引用的文献
1
The history of COPD.慢性阻塞性肺疾病的历史。
Int J Chron Obstruct Pulmon Dis. 2006;1(1):3-14. doi: 10.2147/copd.2006.1.1.3.
2
The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD.皮质类固醇与长效β2受体激动剂联合治疗在慢性阻塞性肺疾病（COPD）加重预防中的作用。
Int J Chron Obstruct Pulmon Dis. 2006;1(4):345-54. doi: 10.2147/copd.2006.1.4.345.
3
4
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.慢性阻塞性肺疾病诊断、管理和预防全球策略：GOLD执行摘要
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. doi: 10.1164/rccm.200703-456SO. Epub 2007 May 16.
5
Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists.与长效β2受体激动剂相比，噻托溴铵在稳定期慢性阻塞性肺疾病（COPD）患者中引起氧饱和度下降的可能性较小。
Respir Med. 2007 Aug;101(8):1798-803. doi: 10.1016/j.rmed.2007.02.007. Epub 2007 Mar 30.
6
Treating COPD--the TORCH trial, P values, and the Dodo.治疗慢性阻塞性肺疾病——TORCH试验、P值与渡渡鸟。
N Engl J Med. 2007 Feb 22;356(8):851-4. doi: 10.1056/NEJMe068307.
7
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.沙美特罗与丙酸氟替卡松及慢性阻塞性肺疾病患者的生存率
N Engl J Med. 2007 Feb 22;356(8):775-89. doi: 10.1056/NEJMoa063070.
8
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.噻托溴铵联合安慰剂、沙美特罗或氟替卡松-沙美特罗治疗慢性阻塞性肺疾病：一项随机试验。
Ann Intern Med. 2007 Apr 17;146(8):545-55. doi: 10.7326/0003-4819-146-8-200704170-00152. Epub 2007 Feb 19.
9
The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study.茶碱对稳定期慢性阻塞性肺疾病患者中福莫特罗与噻托溴铵联合用药的附加效应：一项初步研究。
Respir Med. 2007 May;101(5):957-62. doi: 10.1016/j.rmed.2006.09.012. Epub 2006 Oct 23.
10
The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function.慢性阻塞性肺疾病症状与肺过度充气之间的联系及其对运动和功能的影响。
Am J Med. 2006 Oct;119(10 Suppl 1):21-31. doi: 10.1016/j.amjmed.2006.08.004.
Zotero 插件